KRAS and colorectal carcinoma: Similarly, in another study, CRC patients with concomitant mutations of KRAS and PIK3CA lead to poor clinicopathological parameters, including the location of the tumor at the proximal colon, the poorly differentiated state of the tumor, and significantly elevated levels of CA-199 and CA125 [81].